Renaissance Technologies LLC Has $323,000 Holdings in Immunic, Inc. (NASDAQ:IMUX)

Renaissance Technologies LLC decreased its stake in shares of Immunic, Inc. (NASDAQ:IMUX) by 61.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 291,087 shares of the company’s stock after selling 456,184 shares during the period. Renaissance Technologies LLC owned 0.32% of Immunic worth $323,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Immunic during the 1st quarter valued at about $25,000. Sierra Summit Advisors LLC acquired a new stake in Immunic in the 4th quarter valued at approximately $487,000. Ikarian Capital LLC grew its holdings in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. grew its holdings in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Immunic in the 1st quarter valued at approximately $9,266,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.40 on Friday. Immunic, Inc. has a 1-year low of $0.95 and a 1-year high of $2.11. The firm has a market capitalization of $126.11 million, a PE ratio of -0.93 and a beta of 1.84. The business’s 50 day moving average is $1.49 and its 200-day moving average is $1.34.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period in the prior year, the company posted ($0.54) EPS. On average, sell-side analysts predict that Immunic, Inc. will post -0.92 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. B. Riley assumed coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th. Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Leerink Partnrs raised Immunic to a “strong-buy” rating in a report on Monday, September 9th. Finally, StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.